Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10903862 | Experimental Cell Research | 2015 | 10 Pages |
Abstract
Cell surface Gb3 expression is a likely tumour biomarker for acquired cisplatin resistance of NSCLC and MPM cells. Tumour cell resistance to MDR1 inhibitors of cell surface MDR1 and Gb3 could explain the aggressiveness of NSCLC and MPM. Therapy with GCS activity inhibitors or toxin targeting of the Gb3 receptor may substantially reduce acquired cisplatin drug resistance of NSCLC and MPM cells.
Keywords
Multidrug resistance-associated protein 1 (MRP1)GCsMPMMDR1Gb3malignant pleural mesothelioma (MPM)GSLMRP1PPMPglycosphingolipidLung cancerNSCLCNon-small cell lung cancercisplatincyclosporin AAcquired drug resistanceMultidrug Resistance-associated Protein 1globotriaosylceramideglucosylceramide synthase
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Andreas Tyler, Anders Johansson, Terese Karlsson, Shyam Kumar Gudey, Thomas Brännström, Kjell Grankvist, Parviz Behnam-Motlagh,